Quetiapine ( DrugBank: Quetiapine )
2 diseases
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 6 | Parkinson disease | 4 |
| 13 | Multiple sclerosis/Neuromyelitis optica | 1 |
6. Parkinson disease
Clinical trials : 2,298 / Drugs : 2,202 - (DrugBank : 350) / Drug target genes : 188 - Drug target pathways : 202
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04373317 (ClinicalTrials.gov) | May 1, 2022 | 29/4/2020 | Pimavanserin vs. Quetiapine for the Treatment Parkinson's Psychosis | CSP #2015 - Multicenter, Randomized, Double-blind Comparator Study of Antipsychotics Pimavanserin and Quetiapine for Parkinson''s Disease Psychosis (C-SAPP) | Parkinson's Disease Psychosis | Drug: Pimavanserin;Drug: Quetiapine | VA Office of Research and Development | NULL | Not yet recruiting | 40 Years | N/A | All | 358 | Phase 4 | United States |
| 2 | NCT04164758 (ClinicalTrials.gov) | October 23, 2019 | 13/11/2019 | Study to Evaluate Safety and Daytime Sedation in Subjects With Parkinson's Disease With Neuropsychiatric Symptoms Treated With Pimavanserin or Low-Dose Quetiapine | A Pilot Randomized, Double-blind, Placebo-controlled Study to Evaluate Safety and Daytime Sedation in Subjects With Parkinson's Disease With Neuropsychiatric Symptoms Treated With Pimavanserin or Low-Dose Quetiapine | Parkinson's Disease | Drug: Pimavanserin;Other: Placebo;Drug: Quetiapine | ACADIA Pharmaceuticals Inc. | NULL | Terminated | 50 Years | 85 Years | All | 11 | Phase 2 | United States |
| 3 | EUCTR2004-002608-13-GB (EUCTR) | 16/05/2005 | 19/04/2005 | Pragmatic Randomised Control Trial of Quetiapine for psychosis in Parkinson’s Disease - Quetiapine for psychosis in Parkinson’s disease | Pragmatic Randomised Control Trial of Quetiapine for psychosis in Parkinson’s Disease - Quetiapine for psychosis in Parkinson’s disease | Parkinson's Disease with psychosis | Trade Name: Seroquel Product Name: Seroquel Trade Name: Seroquel Product Name: Seroquel | King’s College London & King’s College Hospital | NULL | Not Recruiting | Female: yes Male: yes | 60 | Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): no Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): yes | United Kingdom | ||
| 4 | NCT00043849 (ClinicalTrials.gov) | July 2002 | 14/8/2002 | Treatment of Agitation/Psychosis in Dementia/Parkinsonism (TAP/DAP) | Treatment of Agitation/Psychosis in Dementia/Parkinsonism (TAP/DAP) | Dementia;Parkinson Disease | Drug: Quetiapine | National Institute on Aging (NIA) | NULL | Completed | 50 Years | N/A | Both | 60 | Phase 4 | United States |
13. Multiple sclerosis/Neuromyelitis optica
Clinical trials : 3,342 / Drugs : 2,355 - (DrugBank : 406) / Drug target genes : 269 - Drug target pathways : 241
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT02087631 (ClinicalTrials.gov) | December 2014 | 12/3/2014 | Safety and Tolerability of Quetiapine in Multiple Sclerosis | A Dose-finding, Safety and Tolerability Trial of Extended-release Quetiapine in Relapsing-remitting and Progressive Multiple Sclerosis | Multiple Sclerosis | Drug: Extended-release quetiapine fumarate | University of Calgary | Multiple Sclerosis Society of Canada | Completed | 18 Years | 65 Years | All | 14 | Phase 1/Phase 2 | Canada |